Questcor Buyout Shocks Short Sellers

Questcor's surprise deal with Mallinckrodt causes a huge problem for short sellers.

Apr 8, 2014 at 6:30PM

Activist short seller Andrew Left's Citron Research frequently uses the phrase: "It's never a problem until it's a problem." Monday's news about specialty pharmaceutical firm Mallinckrodt's (NYSE:MNK) acquisition of Questcor Pharmaceuticals (NASDAQ:QCOR) put a new twist on the saying -- and caused serious problems for investors heeding Citron's advice.

Mallinckrodt plans to buy Questcor for $30 per share in cash plus throw in another 0.897 shares of its stock for each share held by Questcor shareholders. That equates to $86 per share, which is higher than the highest level Questcor's stock has ever been and represents a 27% premium over the closing share price on April 4. That's great news for Questcor investors, but horrible news for those who sold the stock short based on Citron's online articles.

Qcor Logo

Source: Questcor Pharmaceuticals. 

A tale of two perspectives
Some could look at Questcor's ascendance of the past few years as a story of a solid management team taking a drug that's been around for decades and creating fantastic new opportunities. Acthar gel was indeed first approved by the Food and Drug Administration back in 1952. And under CEO Don Bailey's helm, Questcor has successfully pursued several new markets for the drug, resulting in the company's stock shooting up more than 1,300% over the last five years.

Others, particularly Citron Research, hold another perspective altogether. Citron first blasted Questcor in July 2012, alleging that the company was "a scheme, not a business." According to Citron at that time, Questcor's stock would hit single digits within 18 months. 

What actually happened over the next 18 months? Citron continued to regularly publish articles attacking Questcor's marketing of Acthar. There were some times along the way where Citron's argument appeared to possibly be on track. In September 2012, Aetna announced its decision to only reimburse for use of Acthar as a treatment for infantile spasms because of lack of documented efficacy. More recently, Citron cited a lab study that allegedly found little to none of the active ingredient, ACTH, that is supposed to be in Acthar in samples of the drug.

Citron's negative articles certainly took their toll on Questcor. Investors experienced a roller-coaster ride over the last couple of years, with the stock losing 20% or more of its value multiple times. However, Questcor never hit single digits and only once drifted below $20 per share for a short period.

Last laugh?
Quite a few people seem to have agreed with Citron. As of March 14 of this year, Questcor's short percentage of float stood at 38.3%. With this week's development, though, investors holding a bullish viewpoint appear to have the last laugh. Anyone who bought shares before Citron's first allegation and held on would now have gains in the neighborhood of 60%.

That laugh would have likely been even jollier without the issues raised by Citron, though. Mallinckrodt's offer price is only 18 times trailing earnings. That's dirt cheap for a biotech buyout.

Last year's big biotech deal between Amgen (NASDAQ:AMGN) and Onyx went for a price tag of $9.7 billion net of Onyx's cash. Onyx had just reported a loss in the previous quarter on revenue of $153 million.

By comparison, in its last quarter Questcor reported earnings of almost $90 million on revenue of $242.8 million. And it's not that things were slowing down. That revenue figure reflected a 50% year-over-year increase. Earnings were 45% higher than the same quarter in the previous year.

Probably the key difference was that Amgen paid for what it saw as a solid and bright future for Onxy's Kyprolis. Several analysts think the multiple myeloma drug will hit peak annual sales of over $2 billion within the next several years.

Thanks in no small part to Citron Research, there's a cloud hanging over Acthar that makes its future appear less solid and bright. As a result, Questcor fetched a lot less than it could have if there wasn't any uncertainty.

However, if history is any guide, Questcor -- and now Mallinckrodt -- won't face as dire an outcome as the short sellers predict. Some current Questcor shareholders might decide to hang on for the ride with the Mallinckrodt stock coming their way soon. Others might choose to take the money and run. Taking hefty profits is never a problem. 

3 stocks to own for the rest of your life
You won't be able to own Questcor for much longer, but it's not a bad investing strategy to find stocks that you could hold for a long time. As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal "The Motley Fool's 3 Stocks to Own Forever." These picks are free today! Just click here now to uncover the three companies we love. 

Keith Speights has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers